BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 34738358)

  • 1. Assessment of PD-L1 expression in patients with neuroblastoma and renal tumors.
    Şener S; Poyraz A; Okur A; Pınarlı FG; Karadeniz C
    Turk J Pediatr; 2021; 63(5):758-766. PubMed ID: 34738358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of Programmed Cell Death Ligand 1 and Associated Lymphocyte Infiltration in Olfactory Neuroblastoma.
    London NR; Rooper LM; Bishop JA; Xu H; Bernhardt LJ; Ishii M; Hann CL; Taube JM; Izumchenko E; Gaykalova DA; Gallia GL
    World Neurosurg; 2020 Mar; 135():e187-e193. PubMed ID: 31785431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues.
    Majzner RG; Simon JS; Grosso JF; Martinez D; Pawel BR; Santi M; Merchant MS; Geoerger B; Hezam I; Marty V; Vielh P; Daugaard M; Sorensen PH; Mackall CL; Maris JM
    Cancer; 2017 Oct; 123(19):3807-3815. PubMed ID: 28608950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Checkpoint Inhibition Followed by Tumor Infiltration of Dendritic Cells in Murine Neuro-2a Neuroblastoma.
    Inoue S; Horiuchi Y; Setoyama Y; Takeuchi Y; Beck Y; Murakami T; Odaka A
    J Surg Res; 2020 Sep; 253():201-213. PubMed ID: 32380346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of Immunomodulatory Molecules PD-1, PD-L1, and PD-L2, and their Relationship With Clinicopathologic Characteristics in Endometrial Cancer.
    Sungu N; Yildirim M; Desdicioglu R; Başaran Aydoğdu Ö; Kiliçarslan A; Tatli Doğan H; Kiliç Yazgan A; Akyol M; Erdoğan F
    Int J Gynecol Pathol; 2019 Sep; 38(5):404-413. PubMed ID: 30134343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Negative influence of programmed death-1-ligands on the survival of esophageal cancer patients treated with chemotherapy.
    Tanaka K; Miyata H; Sugimura K; Kanemura T; Hamada-Uematsu M; Mizote Y; Yamasaki M; Wada H; Nakajima K; Takiguchi S; Mori M; Doki Y; Tahara H
    Cancer Sci; 2016 Jun; 107(6):726-33. PubMed ID: 27015293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of Programmed Death Receptor 1 (PD-1) Gene and Its Ligand (PD-L1) in Patients with Laryngeal Cancer.
    Kowalski A; Malinowska K; Olszewski J; Zielińska-Bliźniewska H
    Biomolecules; 2021 Jul; 11(7):. PubMed ID: 34356594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease.
    Srinivasan P; Wu X; Basu M; Rossi C; Sandler AD
    PLoS Med; 2018 Jan; 15(1):e1002497. PubMed ID: 29377881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Programmed cell death protein 1 and its ligands regulate immune balance in allergic rhinitis].
    Wen SL; Li F; Zhao F; Zuo JJ; Deng YQ; Zhang W; Tao ZZ
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 Apr; 55(4):384-390. PubMed ID: 32306637
    [No Abstract]   [Full Text] [Related]  

  • 10. Programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) expression in fumarate hydratase-deficient renal cell carcinoma.
    Alaghehbandan R; Stehlik J; Trpkov K; Magi-Galluzzi C; Condom Mundo E; Pane Foix M; Berney D; Sibony M; Suster S; Agaimy A; Montiel DP; Pivovarcikova K; Michalova K; Daum O; Ondic O; Rotterova P; Dusek M; Hora M; Michal M; Hes O
    Ann Diagn Pathol; 2017 Aug; 29():17-22. PubMed ID: 28807336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Non-Small Cell Lung Carcinoma.
    Del C Monroig-Bosque P; Driver B; Morales-Rosado JA; Deavers M; Tacha D; Bernicker E; Cagle PT; Miller RA
    Arch Pathol Lab Med; 2018 Nov; 142(11):1388-1393. PubMed ID: 29431467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed Cell Death 1 Ligand 1 and Programmed Cell Death 1 Ligand 2 Are Expressed in Conjunctival Invasive Squamous Cell Carcinoma: Therapeutic Implications.
    Wolkow N; Jakobiec FA; Afrogheh AH; Eagle RC; Pai SI; Faquin WC
    Am J Ophthalmol; 2019 Apr; 200():226-241. PubMed ID: 30633894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.
    Yang MW; Fu XL; Jiang YS; Chen XJ; Tao LY; Yang JY; Huo YM; Liu W; Zhang JF; Liu PF; Liu Q; Hua R; Zhang ZG; Sun YW; Liu DJ
    World J Gastroenterol; 2019 Apr; 25(14):1684-1696. PubMed ID: 31011254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Expression and significance of programmed cell death ligand-1 in neuroblastoma tissues].
    Liao R; Sun XF; Zhen ZZ; Huang DS
    Zhonghua Er Ke Za Zhi; 2018 Oct; 56(10):735-740. PubMed ID: 30293276
    [No Abstract]   [Full Text] [Related]  

  • 16. [Expression of PD-1 and PD-L1 in the peripheral blood of advanced non-small-cell lung cancer patients and its implications].
    Xing YF; Pan X; Qian B; Shi MH
    Zhonghua Yi Xue Za Zhi; 2019 Jan; 99(2):111-114. PubMed ID: 30669748
    [No Abstract]   [Full Text] [Related]  

  • 17. Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer.
    Drakes ML; Mehrotra S; Aldulescu M; Potkul RK; Liu Y; Grisoli A; Joyce C; O'Brien TE; Stack MS; Stiff PJ
    J Ovarian Res; 2018 May; 11(1):43. PubMed ID: 29843813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concordance of PD-1 and PD-L1 (B7-H1) in paired primary and metastatic clear cell renal cell carcinoma.
    Eckel-Passow JE; Ho TH; Serie DJ; Cheville JC; Houston Thompson R; Costello BA; Dong H; Kwon ED; Leibovich BC; Parker AS
    Cancer Med; 2020 Feb; 9(3):1152-1160. PubMed ID: 31829518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1, inflammation, non-coding RNAs, and neuroblastoma: Immuno-oncology perspective.
    Nallasamy P; Chava S; Verma SS; Mishra S; Gorantla S; Coulter DW; Byrareddy SN; Batra SK; Gupta SC; Challagundla KB
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):53-65. PubMed ID: 29196189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma.
    Schoenfeld JD; Gjini E; Rodig SJ; Tishler RB; Rawal B; Catalano PJ; Uppaluri R; Haddad RI; Hanna GJ; Chau NG; Rabinowits G; Lorch J; Jo VY; Krane JF; Goguen LA; Annino DJ; Abdelrahman S; Lipschitz M; Margalit DN
    Int J Radiat Oncol Biol Phys; 2018 Sep; 102(1):137-145. PubMed ID: 29960819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.